Pfizer Inc. $PFE Shares Sold by Neville Rodie & Shaw Inc.

Key Points

• Neville Rodie & Shaw Inc. reduced its holdings in Pfizer Inc. by 18.4% during the 2nd quarter, owning 83,460 shares worth approximately $2,023,000.
• Despite this decrease, other institutional investors, such as Bessemer Group Inc. and Alta Advisers Ltd., increased their stakes in Pfizer, reflecting ongoing confidence in the company's prospects.
• Pfizer recently reported quarterly earnings of $0.78 EPS, exceeding analyst expectations, and has set an FY 2025 EPS guidance between $2.900 to $3.100.

Neville Rodie & Shaw Inc. decreased its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 18.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 83,460 shares of the biopharmaceutical company's stock after selling 18,864 shares during the quarter. Neville Rodie & Shaw Inc.'s holdings in Pfizer were worth $2,023,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the company. William B. Walkup & Associates Inc. increased its position in Pfizer by 1.2% during the fourth quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock worth $1,044,000 after buying an additional 454 shares during the period. Members Trust Co increased its holdings in shares of Pfizer by 2.1% in the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock valued at $587,000 after purchasing an additional 467 shares during the period. Sutton Place Investors LLC increased its holdings in shares of Pfizer by 5.6% in the first quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock valued at $224,000 after purchasing an additional 472 shares during the period. MSH Capital Advisors LLC increased its holdings in shares of Pfizer by 1.4% in the first quarter. MSH Capital Advisors LLC now owns 34,585 shares of the biopharmaceutical company's stock valued at $876,000 after purchasing an additional 485 shares during the period. Finally, Signature Estate & Investment Advisors LLC grew its holdings in Pfizer by 2.6% during the first quarter. Signature Estate & Investment Advisors LLC now owns 19,254 shares of the biopharmaceutical company's stock worth $488,000 after acquiring an additional 486 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Morgan Stanley upped their price objective on Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Jefferies Financial Group upped their price objective on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a report on Wednesday, May 21st. HSBC decreased their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Berenberg Bank decreased their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Finally, Citigroup boosted their target price on Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Trading Down 3.8%

NYSE PFE traded down $0.95 during trading hours on Friday, hitting $23.91. 81,158,118 shares of the company's stock were exchanged, compared to its average volume of 37,472,864. The business's 50 day moving average is $24.79 and its 200-day moving average is $24.27. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The firm has a market capitalization of $135.94 billion, a P/E ratio of 12.72, a price-to-earnings-growth ratio of 0.85 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the business posted $0.60 earnings per share. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th were paid a dividend of $0.43 per share. The ex-dividend date was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.2%. Pfizer's dividend payout ratio is currently 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.